Immunosuppressive and Cytotoxic Drugs in Dermatology: A Practical Overview and Personal Perspective

Abstract

French

Background:

Cytotoxic/immunosuppressive drugs are regularly used to treat proliferative diseases of the skin and immunologically mediated inflammatory disorders.

Objective:

The rational use of cytotoxic/immunosuppressive drugs, which depends on the proper selection of both the patient and the drug, is discussed.

Conclusion:

Methotrexate, azathioprine, cyclophosphamide, chlorambucil, cyclosporine, and other related drugs have potential benefits in the treatment of severe recalcitrant cutaneous disease. Patients may survive otherwise fatal disorders, or may improve their life-style and become productive again. However, the beneficial effect of these agents is achieved when the blood level is at or near toxic level. Thus, the prescribing physician should have a familiarity with the potential toxicities and a knowledge of proper monitoring techniques.

Get full access to this article

View all access options for this article.

References

Jeffes

EWB

III Weinstein

. Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol Clin 1995; 13:875–890.

Jeffes

EWB

McCullough

Pittelkow

. Methotrexate therapy of psoriasis: Differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995; 104:183–188.

Groenendal

Rampen

FHJ

. Methotrexate and trimethroprim-sulfamethoxazole — a potentially hazardous combination. Clin Exp Dermatol 1990; 15:358–360.

Roenigk

Jr Auerbach

Maibach

Weinstein

. Methotrexate guidelines — revised. J Am Acad Dermatol 1982; 6:145–154.

Gilbert

Klintmalm

Menter

Silverman

. Methotrexate-induced cirrhosis requiring liver transplantation in three patients. Arch Intern Med 1990; 150:889–891.

Kaplan

. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis: An acceptable risk/benefit ratio. Dig Dis Sci 1985; 30:104–109.

Brown

Perry

. Pityriasis rubra pilaris. Arch Dermatol 1966; 94:636–638.

Wantzin

Thomsen

. Methotrexate in lymphomatoid papulosis. Br J Dermatol 1984; 111:93–95.

Paul

Jorizzo

Fleischer

Jr White

. Low-dose methotrexate therapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1994; 31:620–625.

10.

Metzger

Bohan

Goldberg

. Polymyositis and dermatomyositis: Combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81:182–189.

11.

Kasteier

Callen

. Low-dose methotrexate is an effective, corticosteroid sparing agent for the treatment of cutaneous manifestations of dermatomyositis. J Am Acad Dermatol (In press)

12.

Jorizzo

White

Wise

. Low-dose, weekly methotrexate for unusual neutrophilic vascular reactions. Cutaneous polyarteritis and Behçet's disease. J Am Acad Dermatol 1991; 24:973–978.

13.

Lower

Baughman

. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155:846–851.

14.

Duhra

. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28:466–469.

15.

Kamel

Van de Rijn

Weiss

. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328:1317–1321.

16.

Bachman

Svawitzke

Perkins

. Methotrexate-associated lymphoma in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:325–329.

17.

Snow

Gibson

. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 1995; 32:114–116.

18.

Ostensen

. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol 1992; 28:148–152.

19.

Zimmerman

Esch

. Skin lesions treated with azathioprine and prednisone: Comparison of nontransplant patients and renal transplant recipients. Arch Intern Med 1978; 138:912–914.

20.

Hickey

Maguire

Urowitz

. Monitoring cancer incidence in the rheumatoid arthritis azathioprine registry. Arthritis Rheum 1992 Annu Meeting Suppl: Abstr.

21.

Knowles

Gupta

Shear

Sauder

. Azathioprine hypersensitivity-like reactions — a case report and a review of the literature. Br J Dermatol 1995; 20:353–356.

22.

Kawanishi

Rudolph

Bull

. Azathioprine-induced acute pancreatitis. N Engl J Med 1973; 289:357–358.

23.

Jones

Ashworth

. Azathioprine-induced shock in dermatology patients. J Am Acad Dermatol 1993; 29:795–796.

24.

Bystryn

J-C

Steinman

. The adjuvant therapy of pemphigus. Arch Dermatol 1996; 132:203–212.

25.

Callen

Spencer

Burruss

Holtman

. Azathioprine: An effective, corticosteroid-sparing therapy for recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991; 127:515–522.

26.

Cohen

Tyring

Rády

Callen

. Human papilloma virus type 11 in multiple squamous cell carcinomas in a patient with subacute cutaneous lupus erythematosus. J Am Acad Dermatol 1992; 26:840–845.

27.

Bunch

. Long-term followup of azathioprine for polymyositis. Arthritis Rheum 1980; 23:658–662.

28.

Bottomley

Ford

Cunliffe

Cotterill

. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Dermatol 1995;133:460–462.

29.

Zackheim

Glogau

Fisher

Maibach

. 6-Thiogua-nine treatment of psoriasis: Experience in 81 patients. J Am Acad Dermatol 1994; 30:452–458.

30.

Eibshultz

Baird

Weisman

. Oral 2-chloro-deoxyadenosine in psoriatic arthritis. Arthritis Rheum 1995; 38:1604–1609.

31.

Mutasim

Pelc

Anhalt

. Cicatricial pemphigoid. J Geriatr Dermatol 1994; 2:110–118.

32.

Fauci

Katz

Haynes

Wolff

. Cyclophosphamide therapy of severe necrotizing vasculitis. N Engl J Med 1979; 301:235–238.

33.

Newell

Malkinson

. Pyoderma gangrenosum. Arch Dermatol 1983; 119:495–497.

34.

Pandya

Sontheimer

. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol 1992; 28:1626–1630.

35.

Talar-Williams

Hijazi

Walther

. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124:477–484.

36.

Hashimotos

Takeguchi

. Treatment of Behçet's disease. Curr Opin Rheumatol 1992; 4:31–34.

37.

Burruss

Farmer

Callen

. Chlorambucil is an effective, corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol (In press)

38.

Sinoway

Callen

. Chlorambucil is an effective corticosteroid-sparing agent for dermatomyositis. Arthritis Rheum 1993; 36:319–324.

39.

French Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): Results of a randomized clinical trial on 612 patients. Blood 1990; 75:1414–1421.

40.

Keogh

Spratt

McCosker

. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333:628–633.

41.

Yee

Stanley

Pessa

. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345:955–956.

42.

Ellis

Gorsulowsky

Hamilton

. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256: 3110–3116.

43.

Mrowietz

Färber

Zepelin

HH Henneicke-Von

. Long-term maintenance therapy with cyclosporine and post-treatment survey in severe psoriasis. J Am Acad Dermatol 1995; 33:470–475.

44.

Matis

Ellis

Griffiths

CEM

Lazarus

. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992; 128:1060–1064.

45.

Funy

Alessani

Abu-Elmagund

. Adverse effects associated with the use of FK 506. Transplant Proc 1991; 23:3105–3158.